Table 2. Drugs included in baseline treatment regimens and ever in treatment, by drug resistance status.
| Drug | Baseline regimen, all patients (N = 237) |
Ever in regimen, all patients | Initial regimen, DS (N = 201) |
Ever in regimen, DS |
Initial regimen, DR (N = 36) |
Ever in regimen, DR |
|---|---|---|---|---|---|---|
| Any fluoroquinolone | 220 (92.8) | 229 (96.6) | 190 (94.5) | 196 (97.5) | 30 (83.3) | 33 (91.7) |
| Any injectable agent | 216 (91.1) | 221 (93.2) | 192 (95.5) | 194 (96.5) | 24 (66.7) | 27 (75) |
| Isoniazid | 207 (87.3) | 212 (89.5) | 191 (95) | 196 (97.5) | 16 (44.4) | 16 (44.4) |
| Rifampin | 199 (84) | 205 (86.5) | 182 (90.5) | 188 (93.5) | 17 (47.2) | 17 (47.2) |
| Amikacin | 194 (81.9) | 202 (85.2) | 172 (85.6) | 177 (88.1) | 22 (61.1) | 25 (69.4) |
| Ofloxacin | 190 (80.2) | 197 (83.1) | 172 (85.6) | 176 (87.6) | 18 (50) | 21 (58.3) |
| Ethambutol | 138 (58.2) | 198 (83.5) | 120 (59.7) | 178 (88.6) | 18 (50) | 20 (55.6) |
| Pyrazinamide | 138 (58.2) | 156 (65.8) | 118 (58.7) | 133 (66.2) | 20 (55.6) | 23 (63.9) |
| Levofloxacin | 50 (21.1) | 180 (75.9) | 40 (19.9) | 158 (78.6) | 10 (27.8) | 22 (61.1) |
| Kanamycin | 39 (16.5) | 165 (69.6) | 36 (17.9) | 155 (77.1) | 3 (8.3) | 10 (27.8) |
| Moxifloxacin | 26 (11) | 39 (16.5) | 16 (8) | 20 (10) | 10 (27.8) | 19 (52.8) |
| Cycloserine | 25 (10.5) | 41 (17.3) | 5 (2.5) | 10 (5) | 20 (55.6) | 31 (86.1) |
| Para-aminosalicylic acid | 17 (7.2) | 31 (13.1) | 1 (0.5) | 2 (1) | 16 (44.4) | 29 (80.6) |
| Capreomycin | 15 (6.3) | 27 (11.4) | 0 (0) | 0 (0) | 15 (41.7) | 27 (75) |
| Prothionamide | 14 (5.9) | 22 (9.3) | 0 (0) | 0 (0) | 14 (38.9) | 22 (61.1) |
| Linezolid | 5 (2.1) | 10 (4.2) | 1 (0.5) | 1 (0.5) | 4 (11.1) | 9 (25) |
| Clofazimine | 4 (1.7) | 10 (4.2) | 0 (0) | 0 (0) | 4 (11.1) | 10 (27.8) |
| Streptomycin | 4 (1.7) | 14 (5.9) | 1 (0.5) | 9 (4.5) | 3 (8.3) | 5 (13.9) |
| Imipenem | 3 (1.3) | 7 (3) | 2 (1) | 2 (1) | 1 (2.8) | 5 (13.9) |
| Bedaquiline | 0 (0) | 3 (1.3) | 0 (0) | 0 (0) | 0 (0) | 3 (8.3) |
| Delamanid | 0 (0) | 3 (1.3) | 0 (0) | 0 (0) | 0 (0) | 3 (8.3) |
| Hydrocephalus management | ||||||
| In regimen, all patients | In regimen, DS (N = 201) | In regimen, DR (N = 36) | ||||
| Mannitol | 226 (95.4) | 191 (95) | 35 (97.2) | |||
| Furosemide | 35 (14.8) | 29 (14.4) | 6 (16.7) | |||
| Ventriculoperitoneal shunt | 2 (0.8) | 2 (1) | 0 (0) | |||
| Anti-inflammatory therapies | ||||||
| Dexamethasone | 232 (97.9) | 197 (98) | 35 (97.2) | |||
| Prednisone | 35 (14.8) | 29 (14.4) | 6 (16.7) | |||
* Baseline was defined as receiving within 14 days of admission.
Abbreviations: DS, drug susceptible; DR, drug-resistant.